{"protocolSection":{"identificationModule":{"nctId":"NCT04891913","orgStudyIdInfo":{"id":"SY007002"},"organization":{"fullName":"Suzhou Yabao Pharmaceutical R&D Co., Ltd.","class":"INDUSTRY"},"briefTitle":"SY007 in Patients With Acute Ischemic Stroke","officialTitle":"Phase Ib Clinical Study to Evaluate Safety, Tolerance，Pharmacokinetics and Efficacy of SY-007 After Intravenous Injection in Acute Ischemic Stroke Subjects"},"statusModule":{"statusVerifiedDate":"2022-06","overallStatus":"SUSPENDED","whyStopped":"The sponsor decided to suspend the process","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-07-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2023-12-25","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-12-25","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-05-10","studyFirstSubmitQcDate":"2021-05-17","studyFirstPostDateStruct":{"date":"2021-05-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-06-20","lastUpdatePostDateStruct":{"date":"2022-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Suzhou Yabao Pharmaceutical R&D Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke patients. The immunogenicity of SY-007 will be evaluated and this study will provide the recommended dosage for subsequent clinical trials."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":36,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"15mg SY-007/ Placebo Repeat Dose","type":"EXPERIMENTAL","description":"Intravenous infusion of 15mg SY-007 or placebo twice a day for seven consecutive days.","interventionNames":["Drug: SY-007/ Placebo 15mg"]},{"label":"30mg SY-007/ Placebo Repeat Dose","type":"EXPERIMENTAL","description":"Intravenous infusion of 30mg SY-007 or placebo twice a day for seven consecutive days.","interventionNames":["Drug: SY-007/ Placebo 30mg"]},{"label":"60mg SY-007/ Placebo Repeat Dose","type":"EXPERIMENTAL","description":"Intravenous infusion of 60mg SY-007 or placebo twice a day for seven consecutive days.","interventionNames":["Drug: SY-007/ Placebo 60mg"]}],"interventions":[{"type":"DRUG","name":"SY-007/ Placebo 15mg","description":"15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.","armGroupLabels":["15mg SY-007/ Placebo Repeat Dose"]},{"type":"DRUG","name":"SY-007/ Placebo 30mg","description":"30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.","armGroupLabels":["30mg SY-007/ Placebo Repeat Dose"]},{"type":"DRUG","name":"SY-007/ Placebo 60mg","description":"60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.","armGroupLabels":["60mg SY-007/ Placebo Repeat Dose"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety and tolerance of SY-007","description":"Number of patients with treatment-emergent adverse events and number of patients who died over 90 days","timeFrame":"From Day 0 to Day 90"}],"secondaryOutcomes":[{"measure":"Pharmacokinetics of SY-007","description":"Peak Plasma Concentration (Cmax)","timeFrame":"From Day 0 to Day 7"},{"measure":"Pharmacokinetics of SY-007","description":"Area under the plasma concentration versus time curve (AUC)","timeFrame":"From Day 0 to Day 7"},{"measure":"Pharmacokinetics of SY-007","description":"Time to Cmax (Tmax)","timeFrame":"From Day 0 to Day 7"},{"measure":"Pharmacokinetics of SY-007","description":"Terminal half life (T½)","timeFrame":"From Day 0 to Day 7"},{"measure":"Pharmacokinetics of SY-007","description":"Clearance (CL)","timeFrame":"From Day 0 to Day 7"},{"measure":"Pharmacokinetics of SY-007","description":"Volume of distribution","timeFrame":"From Day 0 to Day 7"},{"measure":"Percentage of Participants With Excellent Outcome in Modified Rankin Scale（mRS) Score at Day 8, Day30, Day60, Day90","description":"Excellent mRS is defined as mRS score of 0 or 1","timeFrame":"Day 8, Day30, Day60, Day90"},{"measure":"Modified Rankin Scale Score at Day 8, Day30, Day60, Day90","description":"Modified Rankin Scale Score range from 0 to 5，higher score mean a worse outcome.","timeFrame":"Day 8, Day30, Day60, Day90"},{"measure":"Percentage of Participants With National Institute of Health Stroke Scale (NIHSS) range from 0 to 1 at Day 8, Day30","timeFrame":"Day 8, Day30"},{"measure":"Change From Baseline in NIHSS Score at Day 8, Day30 range from 0 to 1 at Day 8, Day30","timeFrame":"Day 8, Day30"},{"measure":"Percentage of Participants With Excellent Outcome in Barthel index (BI) Score at Day 8, Day30, Day60, Day 90","description":"Excellent BI outcome is defined as a score of \\>=95. BI consists of 10 items that measure a participant's daily functioning, specifically the activities of daily living and mobility.","timeFrame":"Day 8, Day30, Day60, Day 90"},{"measure":"Change of Cerebral infarction volume before and after treatment","timeFrame":"Baseline, Day 8, Day30"},{"measure":"Immunogenicity of SY-007","description":"Anti-Drug antibody evaluation","timeFrame":"From Day 0 to Day 30"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Aged from18 Years to 80 Years\n* Within 24h after the onset of stroke symptoms (time the patient was last seen well)\n* Score range from 4 to 20 points, inclusive, on the NIHSS at randomization\n* Prior to index stroke, patient was able to perform basic activities of daily living without assistance, mRS score≤1\n* Absence of intracranial hemorrhage on brain CT or MRI\n* Patients or legal representatives can give informed consent\n\nKey Exclusion Criteria:\n\n* Venous thrombolytic therapy or endovascular treatments have been applied for patients; or Patients plan to conduct these kind of treatments.\n* Glasgow score of Patients ≤8\n* Patients are receiving oral anticoagulants or INR\\>3.0\n* Baseline blood platelet counts \\<80\\*109/L\n* NIHSS score could not been obtained at baseline\n* FPG levels \\< 50mg/dL or \\>400mg/dL\n* Patients with Kidney disorder eGFR \\<30 mL/min or patients need dialysis\n* Patients with Acute and Chronic hepatitis, or Liver diseases (AST or/and ALT \\>2 × ULN(upper limit normal))\n* systolic blood pressure≥220mmHg or/and diastolic blood pressure≥120mmHg ; or Blood pressure under 90/60mmHg.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School","city":"Nanjing","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}